27.07.2011 • NewsQ2 2011Biogen Idecsales and profits

Biogen Idec Posts Q2 Profit Of $288 Million

Biogen Idec posted second-quarter net income attributable to the company of $288.03 million or $1.18 per share compared to $293.44 million or $1.12 per share last year.

Non-GAAP net income attributable to the company was $332.2 million or $1.36 per share versus $343.2 million or $1.31 per share a year ago.
Quarterly revenues stood flat at $1.21 billion.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.37 per share on revenues of $1.18 billion for the quarter. Analysts' estimates typically exclude special items.

Going ahead, the company revised outlook for 2011. The company now expects earnings per share to be above $4.91. Non-GAAP earnings per share is expected to be above $5.70. Analysts expect earnings of $5.85 per share for the year.

Also, for 2011, revenue growth is expected to be in the low to mid-single digits versus 2010. Analysts anticipate revenues of $4.83 billion for the year.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.